Home/Filings/4/0001209191-24-000467
4//SEC Filing

Harsch Mutya 4

Accession 0001209191-24-000467

CIK 0001566044other

Filed

Jan 2, 7:00 PM ET

Accepted

Jan 3, 5:20 PM ET

Size

9.9 KB

Accession

0001209191-24-000467

Insider Transaction Report

Form 4
Period: 2024-01-01
Harsch Mutya
CHIEF LEGAL OFFICER AND GC
Transactions
  • Tax Payment

    Common Stock

    2024-01-02$2.28/sh161$367149,435 total
  • Award

    Stock Option (right to buy)

    2024-01-01+62,50062,500 total
    Exercise: $2.33Exp: 2033-12-31Common Stock (62,500 underlying)
  • Award

    Common Stock

    2024-01-01+62,500149,596 total
Footnotes (4)
  • [F1]Grant to the Reporting Person of a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
  • [F2]The shares underlying the RSU vest over a period of 4 years. 25% of the shares subject to the award will vest on March 31, 2025 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date.
  • [F3]Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.
  • [F4]The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on March 31, 2025 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date.

Issuer

VYNE Therapeutics Inc.

CIK 0001566044

Entity typeother

Related Parties

1
  • filerCIK 0001727809

Filing Metadata

Form type
4
Filed
Jan 2, 7:00 PM ET
Accepted
Jan 3, 5:20 PM ET
Size
9.9 KB